Methotrexate Comparable to Prednisone for Pulmonary Sarcoidosis

New clinical trial findings from the PREDMETH study indicate that methotrexate is noninferior to prednisone for treating pulmonary sarcoidosis. Presented at the CHEST 2026 Annual Meeting, the trial involved 138 patients and assessed lung capacity over 24 weeks, showing comparable efficacy in maintaining lung function. This provides clinicians with an evidence-based alternative, potentially reducing reliance on corticosteroids and their associated side effects for managing this inflammatory condition.